GlassScriptPhysician profile
Larry C Evans
NPI 1669540522
$6,856.95
in general payments reported to CMS, 2019-2025
36 companies · $582 in 2025
The $582 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $962 · 2020: $534 · 2021: $1,232 · 2022: $1,252 · 2023: $1,367 · 2024: $928 · 2025: $582.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,877.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,876.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,584.66 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $659.87 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $573.34 | 2019-2023 | Xifaxan |
| Celgene Corporation | $431.81 | 2019-2024 | Zeposia |
| Gilead Sciences, INC. | $277.72 | 2019-2023 | |
| Ferring Pharmaceuticals INC. | $253.10 | 2019-2023 | Rebyota |
| Janssen Biotech, INC. | $169.69 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Braintree Laboratories, INC. | $167.61 | 2019-2023 | Sutab |
| Regeneron Healthcare Solutions, INC. | $167.44 | 2022-2024 | Dupixent |
| Genzyme Corporation | $142.49 | 2021-2025 | |
| Ardelyx, INC. | $139.51 | 2022-2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $130.75 | 2020-2022 | |
| Intercept Pharmaceuticals, INC. | $120.79 | 2019-2025 | |
| Medtronic, INC. | $99.80 | 2021-2024 | Endoflip |
| Daiichi Sankyo INC. | $96.55 | 2020-2025 | Injectafer |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $87.30 | 2019 | |
| Pfizer INC. | $86.01 | 2019-2025 | |
| Redhill Biopharma INC. | $82.01 | 2020-2022 | |
| Orphalan INC | $71.71 | 2024-2025 | Cuvrior |
| Merck Sharp & Dohme LLC | $71.36 | 2021-2023 | Dificid |
| Aimmune Therapeutics, INC. | $57.01 | 2025 | Vowst, Zenpep |
| Boston Scientific Corporation | $52.69 | 2019-2025 | Overstitch Nxt Endoscopic Suturing System |
| Pentax of America, INC. | $49.28 | 2023 | C2 Cryoballoon |
| Alfasigma USA, INC. | $48.86 | 2020 | |
| Phathom Pharmaceuticals, INC. | $41.25 | 2024-2025 | Voquezna |
| Qol Medical, LLC | $36.00 | 2022-2023 | Sucraid |
| Fresenius Kabi USA, LLC | $27.26 | 2024 | Idacio |
| Shire North American Group INC | $21.23 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.99 | 2023 | Cyltezo |
| Ipsen Biopharmaceuticals, INC | $19.36 | 2024 | Iqirvo |
| Shield Therapeutics INC | $18.93 | 2023 | Accrufer |
| Sandoz INC. | $17.23 | 2024 | Hyrimoz |
| Madrigal Pharmaceuticals | $16.81 | 2025 | Rezdiffra |
| Mallinckrodt Hospital Products INC. | $16.53 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.